These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31916523)

  • 1. Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects.
    Kotlovskiy MY; Udut EV; Kairov GT; Fisenko VP; Udut VV
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):93-107. PubMed ID: 31916523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia.
    Hong H; Xu ZM; Pang BS; Cui L; Wei Y; Guo WJ; Mao YL; Yang XC
    Chin Med Sci J; 2004 Jun; 19(2):145-9. PubMed ID: 15250255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia.
    Nordøy A; Bønaa KH; Nilsen H; Berge RK; Hansen JB; Ingebretsen OC
    J Intern Med; 1998 Feb; 243(2):163-70. PubMed ID: 9566646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effects after withdrawal of simvastatin on brachial artery endothelial function in patient with coronary heart disease or risk factors].
    Chen H; Ren JY; Wu B; Liu X; Wang RJ; Li LJ; Luo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):531-5. PubMed ID: 17711713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
    Jula A; Marniemi J; Huupponen R; Virtanen A; Rastas M; Rönnemaa T
    JAMA; 2002 Feb; 287(5):598-605. PubMed ID: 11829698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
    de Lorgeril M; Salen P; Guiraud A; Zeghichi S; Boucher F; de Leiris J
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):36-41. PubMed ID: 15871849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
    Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
    Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease.
    Pioruńska-Stolzmann M; Pioruńska-Mikołajczak A
    Pharmacol Res; 2001 Apr; 43(4):359-62. PubMed ID: 11394370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of diabetic dyslipidemia.
    Garg A
    Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins.
    Pearson TA
    Am J Cardiol; 1998 Nov; 82(10A):28S-30S. PubMed ID: 9860353
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
    de Lorgeril M; Salen P; Bontemps L; Belichard P; Geyssant A; Itti R
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):473-8. PubMed ID: 10069684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.